Welcome to our dedicated page for Enzo Biochem SEC filings (Ticker: ENZB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Enzo Biochem's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Enzo Biochem's regulatory disclosures and financial reporting.
Enzo Biochem (ENZB): Schedule 13G/A filed by Beryl Capital entities shows no current stake. Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP, and David A. Witkin reported 0 shares and 0% beneficial ownership of Enzo Biochem common stock (CUSIP 294100102) as of 09/30/2025.
The filing affirms the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. Item 5 indicates ownership of five percent or less of the class. All voting and dispositive powers are listed as 0.